Pharmacokinetic and pharmacodynamic modelling of intravenous, intramuscular and subcutaneous buprenorphine in conscious cats

Página do item simplificado
dc.contributor.authorSteagall, Paulo V.M. [UNESP]
dc.contributor.authorPelligand, Ludovic
dc.contributor.authorGiordano, Tatiana [UNESP]
dc.contributor.authorAuberger, Christophe
dc.contributor.authorSear, John W.
dc.contributor.authorLuna, Stélio Pacca Loureiro [UNESP]
dc.contributor.authorTaylor, Polly M.
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversity of London
dc.contributor.institutionQuotient Bioresearch Ltd.
dc.contributor.institutionUniversity of Oxford
dc.contributor.institutionTaylor Monroe
dc.date.accessioned2014-05-27T11:27:30Z
dc.date.available2014-05-27T11:27:30Z
dc.date.issued2013-01-01
dc.description.abstractObjective To describe simultaneous pharmacokinetics (PK) and thermal antinociception after intravenous (IV), intramuscular (IM) and subcutaneous (SC) buprenorphine in cats. Study design Randomized, prospective, blinded, three period crossover experiment. Animals Six healthy adult cats weighing 4.1±0.5kg. Methods Buprenorphine (0.02mgkg-1) was administered IV, IM or SC. Thermal threshold (TT) testing and blood collection were conducted simultaneously at baseline and at predetermined time points up to 24hours after administration. Buprenorphine plasma concentrations were determined by liquid chromatography tandem mass spectrometry. TT was analyzed using anova (p<0.05). A pharmacokinetic-pharmacodynamic (PK-PD) model of the IV data was described using a model combining biophase equilibration and receptor association-dissociation kinetics. Results TT increased above baseline from 15 to 480minutes and at 30 and 60minutes after IV and IM administration, respectively (p<0.05). Maximum increase in TT (mean±SD) was 9.3±4.9°C at 60minutes (IV), 4.6±2.8°C at 45minutes (IM) and 1.9±1.9°C at 60minutes (SC). TT was significantly higher at 15, 60, 120 and 180minutes, and at 15, 30, 45, 60 and 120minutes after IV administration compared to IM and SC, respectively. IV and IM buprenorphine concentration-time data decreased curvilinearly. SC PK could not be modeled due to erratic absorption and disposition. IV buprenorphine disposition was similar to published data. The PK-PD model showed an onset delay mainly attributable to slow biophase equilibration (t1/2ke0=47.4minutes) and receptor binding (kon=0.011mL ng-1minute-1). Persistence of thermal antinociception was due to slow receptor dissociation (t1/2koff=18.2minutes). Conclusions and clinical relevance IV and IM data followed classical disposition and elimination in most cats. Plasma concentrations after IV administration were associated with antinociceptive effect in a PK-PD model including negative hysteresis. At the doses administered, the IV route should be preferred over the IM and SC routes when buprenorphine is administered to cats. © 2012 Association of Veterinary Anaesthetists and the American College of Veterinary Anesthesiologists.en
dc.description.affiliationDepartment of Veterinary Surgery and Anesthesiology School of Veterinary Medicine and Animal Science Sao Paulo State University, UNESP Botucatu, São Paulo
dc.description.affiliationRoyal Veterinary College University of London, Hatfield, Hertfordshire
dc.description.affiliationQuotient Bioresearch Ltd., Fordham, Cambridgeshire
dc.description.affiliationNuffield Department of Anaesthetics University of Oxford, Oxford
dc.description.affiliationTaylor Monroe, Little Downham, Ely
dc.description.affiliationUnespDepartment of Veterinary Surgery and Anesthesiology School of Veterinary Medicine and Animal Science Sao Paulo State University, UNESP Botucatu, São Paulo
dc.format.extent83-95
dc.identifierhttp://dx.doi.org/10.1111/j.1467-2995.2012.00779.x
dc.identifier.citationVeterinary Anaesthesia and Analgesia, v. 40, n. 1, p. 83-95, 2013.
dc.identifier.doi10.1111/j.1467-2995.2012.00779.x
dc.identifier.issn1467-2987
dc.identifier.issn1467-2995
dc.identifier.lattes4473260410099623
dc.identifier.orcid0000-0001-5312-9076
dc.identifier.scopus2-s2.0-84871372058
dc.identifier.urihttp://hdl.handle.net/11449/74223
dc.identifier.wosWOS:000318037600012
dc.language.isoeng
dc.relation.ispartofVeterinary Anaesthesia and Analgesia
dc.relation.ispartofjcr2.064
dc.relation.ispartofsjr0,800
dc.relation.ispartofsjr0,800
dc.rights.accessRightsAcesso restrito
dc.sourceScopus
dc.subjectAnalgesia
dc.subjectBuprenorphine
dc.subjectCat
dc.subjectPharmacokinetics
dc.subjectRoutes of administration
dc.subjectThermal nociceptive threshold
dc.subjectbuprenorphine
dc.subjectnarcotic analgesic agent
dc.subjectanimal
dc.subjectanimal disease
dc.subjectblood
dc.subjectcat
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectcrossover procedure
dc.subjectfemale
dc.subjectintramuscular drug administration
dc.subjectintravenous drug administration
dc.subjectmale
dc.subjectrandomized controlled trial
dc.subjectsubcutaneous drug administration
dc.subjectAnalgesics, Opioid
dc.subjectAnimals
dc.subjectCats
dc.subjectCross-Over Studies
dc.subjectFemale
dc.subjectInjections, Intramuscular
dc.subjectInjections, Intravenous
dc.subjectInjections, Subcutaneous
dc.subjectMale
dc.subjectAnimalia
dc.titlePharmacokinetic and pharmacodynamic modelling of intravenous, intramuscular and subcutaneous buprenorphine in conscious catsen
dc.typeArtigo
dcterms.licensehttp://olabout.wiley.com/WileyCDA/Section/id-406071.html
unesp.author.lattes4473260410099623
unesp.author.orcid0000-0001-5312-9076[6]
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Medicina Veterinária e Zootecnia, Botucatupt

Arquivos

Coleções

Artigos - Cirurgia e Anestesiologia Veterinária - FMVZ